Uveitis follow-up
| All uveitis (n=147) | ANA+JIA (n=58) | ANA−JIA (n=24) | ERA (n=9) | Idiopathic (n=36) | Sarcoidosis (n=9) | Others uveitis* (n=11) | |
| Uveitis in remission off steroids† | |||||||
| Number of cases, n (%) | 45 (30) | 18 (31) | 5 (20) | 5 (55) | 11 (30) | 3 (33) | 3 (27) |
| Follow-up (month), mean±SD (median) | 48±32 (48) | 58±36 (51.5) | 46±37 (60) | 31±31 (13) | 56±43 (48) | 51±29 (48) | 45±39 (48) |
| Age (years) at last consultation, mean (median) | 11.4 (11) | 10 (10) | 10 (9) | 13.8 (15) | 14.1 (14) | 17 | 13.2 (11) |
| DMARDs | 13 (27) | 10 (55) | 0 | 0 | 1 (9) | 1 (33) | 1 (10) |
| Biological therapy | 13 (29) | 5 (27) | 1 (25) | 2 (33) | 1 (9) | 0 | 2 (20) |
| Adalimumab | 8 | 3 | 1 | 2 | 1 | 0 | 1 |
| Etanercept | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Abatacept | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anakinra | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Infliximab | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Duration of remission (month) | 24±20 (6 – 76) | 22±19 (12) | 38±29(24) | 15±8 (12) | 25±2124 | 12 (12) | 30±36 (6) |
| Inactive uveitis on topical steroids‡ | |||||||
| Number of cases, n (%) | 56 (39) | 21 (35) | 13 (54) | 2 (22) | 13 (36) | 2 (22) | 5 (45) |
| Follow-up (month), mean±SD (median) | 51.4±39 (42) | 67±43 (72) | 51±38.5 (42) | 22±10 (22.5) | 35±2630 | 69.5±20 (69.5) | 40.6±5218 |
| Age at last consultation (years), mean (n–N) | 12 (2–21) | 11.4 (2–16) | 10.7 (5–18) | 15(14–15) | 12.6 (2.5–17) | 16.25 (11.5–21) | 14.4 (5–21) |
| Topical corticosteroids | 56 | 21 | 13 | 2 | 13 | 2 | 5 |
| Systemic corticosteroids | 10 (21) | 1 (5) | 1 (8) | 0 | 2 (17) | 2 | 4 (44) |
| DMARDs | 37 (66) | 18 (86) | 11(85) | 0 | 6 (50) | 1 (50) | 1 (11) |
| Biological therapy | 26 (45) | 13 (62) | 9 (70) | 0 | 2 (17) | 0 | 2 (11) |
| Adalimumab | 23 | 13 | 7 | 0 | 2 | 0 | 1 |
| Etanercept | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Anakinra | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Infliximab | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Duration of remission/inactivity (month), mean±SD (median) | 13.8±11 (4 – 48) | 14.5±11 (12) | 19.5±16 (12) | 9±4.2 (9) | 9.6±8.6 (3) | 9±4.2 (9) | 9.6±3.2 (2) |
| Active uveitis§ | |||||||
| Number of cases, n (%) | 46 (31) | 19 (33) | 6 (26) | 2 (11) | 12 (34) | 4 (44) | 3 (27) |
| Follow-up (month), mean±SD (median) | 54±41 (6 –168) | 64±40 (66) | 73.5±46 (60) | 3 | 30.7±22 (27) | 45.6±31 (24) | 45.6±33.8 (33) |
| Age at last consultation (years), mean (n–N) | 11.4 (4–18) | 10 (4–17) | 11.5 (6.5–17) | 14.5 | 10.8 (6.5–17) | 13.7 (9.5–8) | 14.6 (12.5–18) |
| Topical corticosteroids | 48 | 19 | 6 | 1 | 12 | 4 | 5 |
| Systemic corticosteroids | 9 (19) | 4 (21) | 1 (17) | 0 | 4 (33) | 2 (50) | 0 |
| DMARDs | 31 (73) | 15 (79) | 6 (100) | 0 | 6 (50) | 3 (75) | 4 (40) |
| Biological therapy | 25 (52) | 15 (79) | 4 (67) | 0 | 4 (33) | 2 (50) | 1 (10) |
| Adalimumab | 24 | 15 | 4 | – | 3 | 1 | 1 |
| Etanercept | 2 | 1 | 1 | – | 0 | 0 | 0 |
| Abatacept | 2 | 0 | 1 | – | 0 | 1 | 0 |
| Tocilizumab | 0 | 0 | 0 | – | 1 | 0 | 0 |
| Infliximab | 5 | 2 | 1 | – | 1 | 1 | 0 |
| SUN classification, cells, n (%) | |||||||
| 0+ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0.5+ | 27 (58) | 13 (68) | 4 (67) | 1 | 7 (58) | 1 (75) | 1 (33) |
| 1+¶ | 19 (42) | 6 (32) | 2 (33) | 1 | 5 (42) | 3 (25) | 2 (67) |
*Other aetiologies: 4 Behçet disease, 1 Muckle-Wells syndrome, 1 Cogan syndrome, 2 TINU syndrome, 2 Vogt-Koyanagi-Harada syndrome, 1 systemic-onset JIA.
†According to SUN criteria: patients with inactive disease for at least 6 months after discontinuing all topical steroids.
‡According to SUN criteria: grade >0.5 cells apply to the anterior chamber.
§According to SUN criteria: grade 0 cells apply to the anterior chamber.
¶No patient had a score of >1 at the latest follow-up.
ANA, antinuclear antibody; DMARD, disease-modifying antirheumatic drug; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis.